A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus-Reference-Cited by-同舟云学术

A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus

Published:2020-01-31 Issue:4 Volume:94 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Smith Andrew¹²,Rodriguez Laura¹,El Ghouayel Maya¹,Nogales Aitor¹,Chamberlain Jeffrey M.¹,Sortino Katherine¹,Reilly Emma¹³,Feng Changyong⁴,Topham David J.¹³^ORCID,Martínez-Sobrido Luis¹,Dewhurst Stephen¹^ORCID

Affiliation:

1. Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA

2. Medical Scientist Training Program, University of Rochester, Rochester, New York, USA

3. David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, New York, USA

4. Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA

Abstract

Seasonal influenza infection remains a major cause of disease and death, underscoring the need for improved vaccines. Among current influenza vaccines, the live attenuated influenza vaccine (LAIV) is unique in its ability to elicit T-cell immunity to the conserved internal proteins of the virus. Despite this, LAIV has shown limited efficacy in recent years. One possible reason is that the conserved, internal genes of all current LAIVs derive from virus strains that were isolated between 1957 and 1960 and that, as a result, do not resemble currently circulating influenza viruses. We have therefore developed and tested a new LAIV, based on a currently circulating pandemic strain of influenza. Our results show that this new LAIV elicits improved protective immunity compared to a more conventional LAIV.

Funder

HHS | National Institutes of Health

U.S. Department of Defense

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/JVI.01065-19

Reference63 articles.

1. Estimates of deaths associated with seasonal influenza—United States, 1976–2007;Centers for Disease Control and Prevention;MMWR Morb Mortal Wkly Rep,2010

2. Influenza- and RSV-associated hospitalizations among adults

3. Centers for Disease Control and Prevention. 2018. Summary of the 2017–2018 influenza season. Centers for Disease Control and Prevention, Atlanta, GA. https://www.cdc.gov/flu/about/season/flu-season-2017-2018.htm. Accessed 9 February 2019.

4. Centers for Disease Control and Prevention. 2018. Estimated influenza illnesses, medical visits, hospitalizations, and deaths in the United States: 2017–2018 influenza season. Centers for Disease Control and Prevention, Atlanta, GA. https://www.cdc.gov/flu/about/burden/estimates.htm. Accessed 9 February 2019.

5. Centers for Disease Control and Prevention. 2018. June 2018 ACIP minutes. Centers for Disease Control and Prevention, Atlanta, GA. https://www.cdc.gov/vaccines/acip/meetings/index.html. Accessed 9 February 2019.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An intranasal influenza virus vector vaccine protects against Helicobacter pylori in mice;Journal of Virology;2024-03-19

2. Nucleoprotein as a Promising Antigen for Broadly Protective Influenza Vaccines;Vaccines;2023-11-23

3. Generation of a recombinant temperature-sensitive influenza D virus;Scientific Reports;2023-03-07

4. Silencing Transcription from an Influenza Reverse Genetics Plasmid in E. coli Enhances Gene Stability;ACS Synthetic Biology;2023-01-30

5. Optimizing the Live Attenuated Influenza A Vaccine Backbone for High-Risk Patient Groups;Journal of Virology;2022-10-26